$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

$abeo Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019459 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.646M	$7.123M	$3.997M
YoY Change	72.2%	78.21%	-5.37%
% of Gross Profit
Research & Development	$9.218M	$7.207M	$8.041M
YoY Change	8.15%	-10.37%	-23.75%
% of Gross Profit
Depreciation & Amortization	$487.0K	$491.0K	$661.0K
YoY Change	-20.81%	-25.72%	-18.5%
% of Gross Profit
Operating Expenses	$17.86M	$14.33M	$12.04M
YoY Change	18.16%	19.04%	-18.49%
Operating Profit	-$17.86M	-$14.33M	-$12.04M
YoY Change	69.26%	19.04%	-41.54%
Interest Expense	$1.072M	$952.0K	$101.0K
YoY Change	241.4%	842.57%	-150.5%
% of Operating Profit
Other Income/Expense, Net	$224.0K	$162.0K	$2.668M
YoY Change	-103.49%	-93.93%	-311.75%
Pretax Income	$7.406M	-$31.58M	-$9.107M
YoY Change	-144.47%	246.74%	-56.2%
Income Tax
% Of Pretax Income
Net Earnings	$7.406M	-$31.58M	-$9.107M
YoY Change	-144.47%	246.74%	-56.2%
Net Earnings / Revenue
Basic Earnings Per Share	$0.19	-$1.16	-$0.54
Diluted Earnings Per Share	-$0.26	-$1.16	-$0.54
COMMON SHARES
Basic Shares Outstanding	41.19M shares	27.36M shares	17.71M shares
Diluted Shares Outstanding	51.23M shares	27.32M shares	16.90M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$122.7M	$62.34M	$40.36M
YoY Change	233.7%	54.45%	28.9%
Cash & Equivalents	$34.43M	$17.56M	$4.680M
Short-Term Investments	$88.28M	$44.79M	$35.68M
Other Short-Term Assets	$1.556M	$2.149M	$1.961M
YoY Change	1.1%	9.59%	-75.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$1.640M	$2.232M	$519.0K
Total Short-Term Assets	$125.9M	$66.73M	$42.84M
YoY Change	185.9%	55.74%	9.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.975M	$3.767M	$5.298M
YoY Change	-57.73%	-28.9%	-66.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$114.0K	$99.00K
YoY Change	-7.41%	15.15%	395.0%
Total Long-Term Assets	$8.099M	$8.103M	$10.50M
YoY Change	-14.85%	-22.84%	-34.24%
TOTAL ASSETS
Total Short-Term Assets	$125.9M	$66.73M	$42.84M
Total Long-Term Assets	$8.099M	$8.103M	$10.50M
Total Assets	$134.0M	$74.83M	$53.35M
YoY Change	150.24%	40.27%	-3.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.099M	$3.362M	$2.857M
YoY Change	-10.87%	17.68%	78.45%
Accrued Expenses	$4.924M	$2.791M	$2.569M
YoY Change	-14.48%	8.64%	-57.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.222M
YoY Change
Total Short-Term Liabilities	$16.84M	$11.89M	$7.420M
YoY Change	78.42%	60.23%	-39.86%
LONG-TERM LIABILITIES
Long-Term Debt	$16.13M	$18.08M	$0.00
YoY Change
Other Long-Term Liabilities	$27.79M	$53.74M	$27.19M
YoY Change	-20.07%	97.69%	138.63%
Total Long-Term Liabilities	$16.13M	$18.08M	$27.19M
YoY Change	-53.59%	-33.5%	138.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.84M	$11.89M	$7.420M
Total Long-Term Liabilities	$16.13M	$18.08M	$27.19M
Total Liabilities	$60.76M	$83.71M	$34.61M
YoY Change	37.46%	141.9%	45.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$773.7M	-$781.1M	-$704.4M
YoY Change	7.29%	10.88%
Common Stock	$417.0K	$276.0K	$179.0K
YoY Change	93.95%	54.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$73.24M	-$8.881M	$18.74M
YoY Change
Total Liabilities & Shareholders Equity	$134.0M	$74.83M	$53.35M
YoY Change	150.24%	40.27%	-3.31%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$7.406M	-$31.58M	-$9.107M
YoY Change	-144.47%	246.74%	-56.2%
Depreciation, Depletion And Amortization	$487.0K	$491.0K	$661.0K
YoY Change	-20.81%	-25.72%	-18.5%
Cash From Operating Activities	-$12.68M	-$14.54M	-$11.70M
YoY Change	23.34%	24.26%	-14.52%
INVESTING ACTIVITIES
Capital Expenditures	$711.0K	$725.0K	$218.0K
YoY Change	2121.88%	232.57%	-311.65%
Acquisitions
YoY Change
Other Investing Activities	-$43.42M	-$7.092M	$2.429M
YoY Change	-928.17%	-391.97%	106.2%
Cash From Investing Activities	-$44.13M	-$7.817M	$2.211M
YoY Change	-946.9%	-453.55%	105.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	73.68M	$25.44M	-$4.000K
YoY Change	1013.39%	-636100.0%
NET CHANGE
Cash From Operating Activities	-12.68M	-$14.54M	-$11.70M
Cash From Investing Activities	-44.13M	-$7.817M	$2.211M
Cash From Financing Activities	73.68M	$25.44M	-$4.000K
Net Change In Cash	16.87M	$3.085M	-$9.537M
YoY Change	991.78%	-132.35%
FREE CASH FLOW
Cash From Operating Activities	-$12.68M	-$14.54M	-$11.70M
Capital Expenditures	$711.0K	$725.0K	$218.0K
Free Cash Flow	-$13.40M	-$15.26M	-$11.92M
YoY Change	29.85%	28.07%	-12.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2023Q1	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023	ABEO	Derivative Liability Measurement Term DerivativeLiabilityMeasurementTerm	P0Y
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount		usd
CY2023Q4	ABEO	Accreted Final Payment Fee AccretedFinalPaymentFee		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1044000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	998000	usd
CY2024Q1	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	4691000	usd
CY2023Q4	us-gaap	Other Loans Payable Current OtherLoansPayableCurrent	4580000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11889000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13422000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4046000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4402000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18079000	usd
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1005000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7207000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8041000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7123000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3997000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	14330000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	12038000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14330000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12038000	usd
CY2024Q1	us-gaap	Interest Income Operating InterestIncomeOperating	843000	usd
CY2023Q1	us-gaap	Interest Income Operating InterestIncomeOperating	364000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	952000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	101000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	17301000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2265000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	162000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	403000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-31578000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9107000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.16
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.16
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27315537	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27315537	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16904024	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16904024	shares
CY2024Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-118000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	64000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31696000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9043000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	14826000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1546000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-14000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6457000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-31578000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-118000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-8881000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26761000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26761000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	770000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-4000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	256000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9107000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	64000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	18740000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	18740000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-31578000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-9107000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	491000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	661000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1546000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	770000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	17301000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2265000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	59000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	117000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	233000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	227000	usd
CY2024Q1	us-gaap	Noncash Contribution Expense NoncashContributionExpense	345000	usd
CY2023Q1	us-gaap	Noncash Contribution Expense NoncashContributionExpense	100000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-252000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	75000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1232000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1199000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-163000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	56000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1690000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-376000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-310000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-308000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14538000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11744000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	725000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	218000	usd
CY2024Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	29343000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	7964000	usd
CY2024Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	22251000	usd
CY2023Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	10393000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7817000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2211000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6417000	usd
CY2024Q1	ABEO	Proceeds From Repayment Settlement Of Restricted Share Awards ProceedsFromRepaymentSettlementOfRestrictedShareAwards	-14000	usd
CY2023Q1	ABEO	Proceeds From Repayment Settlement Of Restricted Share Awards ProceedsFromRepaymentSettlementOfRestrictedShareAwards	-4000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	20000000	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	963000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25440000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3085000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9537000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14811000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14555000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17896000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5018000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17558000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4680000	usd
CY2024Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	338000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	338000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17896000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5018000	usd
CY2024Q1	ABEO	Derivative And Warrant Additions Associated With Loan And Security Agreement DerivativeAndWarrantAdditionsAssociatedWithLoanAndSecurityAgreement	1042000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	607000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	8000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	6000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31600000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9100000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-781100000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	62700000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	75000000.0	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zl9RPmMqyAoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zWGzNhShYrh2">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Other Receivables OtherReceivables	2100000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	2100000	usd
CY2024Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12624762	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10562522	shares
CY2024Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	44969000	usd
CY2024Q1	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	183000	usd
CY2024Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	44786000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	37819000	usd
CY2023	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	66000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	37753000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17249000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16524000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13482000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12991000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3767000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3533000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	500000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	700000	usd
CY2023Q4	ABEO	Warrant Liabilities WarrantLiabilities	31352000	usd
CY2024Q1	ABEO	Fair Value Adjustment Of Warrants Issued FairValueAdjustmentOfWarrantsIssued	220000	usd
CY2024Q1	ABEO	Gain Loss Recognized In Earnings From Change In Fair Value GainLossRecognizedInEarningsFromChangeInFairValue	17118000	usd
CY2024Q1	ABEO	Warrant Liabilities WarrantLiabilities	48690000	usd
CY2024Q1	ABEO	Fair Value Of Derivatives Issued FairValueOfDerivativesIssued	822000	usd
CY2024Q1	us-gaap	Derivative Loss On Derivative DerivativeLossOnDerivative	183000	usd
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1005000	usd
CY2024Q1	ABEO	Derivative Liability Measurement Term DerivativeLiabilityMeasurementTerm	P3Y3M
CY2024Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zeggXpZWBXK4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_829_zXMl4o7IFTy5">SETTLEMENT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 12, 2021, the Company entered into a settlement agreement (“Settlement Agreement”) with the Company’s prior licensor REGENXBIO Inc. (“REGENXBIO”) to resolve all existing disputes between the parties. In accordance with the Settlement Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_909_eus-gaap--SettlementLiabilitiesCurrent_iI_pn5n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zRm2T5bNXVAf" title="Settlement liabilities, current">30.0</span> million, payable as follows: <span id="xdx_909_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_z6DQNwkphNZ6" title="Loss contingency settlement agreement terms">(1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement (paid in November 2022), and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2024, the Company recorded the payable due to REGENXBIO in the condensed consolidated balance sheets based on the present value of the remaining payments due to REGENXBIO under the Settlement Agreement using an effective interest rate of <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zDoA97UAS4p2" title="Effective interest rate stated percentage">9.6</span>%. The present value of the amount due in November 2024 was $<span id="xdx_904_eus-gaap--LongTermDebt_iI_pn5n6_c20240331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zcn5y9j3YgQ" title="Long term debt">4.7</span> million and $<span id="xdx_901_eus-gaap--LongTermDebt_iI_pn5n6_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--AwardDateAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zSbap4iAr1sa" title="Long term debt">4.6</span> million as of March 31, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2024Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1328000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3688000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1463000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2297000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2791000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5985000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1170000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5090000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1044000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	998000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4046000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4402000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	5090000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5400000	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	334000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	415000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	74000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	39000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	23000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	18000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	431000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	472000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	591000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1555000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	791000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	807000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	823000	usd
CY2024Q1	ABEO	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1693000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6260000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P63M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.073	pure
CY2024Q1	ABEO	Future Cash Receipts From Operating Sublease Remainder Of Fiscal Year FutureCashReceiptsFromOperatingSubleaseRemainderOfFiscalYear	477000	usd
CY2024Q1	ABEO	Future Cash Receipts From Operating Sublease Next Twelve Months FutureCashReceiptsFromOperatingSubleaseNextTwelveMonths	485000	usd
CY2024Q1	ABEO	Future Cash Receipts From Operating Sublease FutureCashReceiptsFromOperatingSublease	962000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2024Q1	ABEO	Accreted Final Payment Fee AccretedFinalPaymentFee	74000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1995000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	18079000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6667000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	8889000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4444000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	20000000	usd
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1788000	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.75
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1788000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.75
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16000000.0	usd
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	7000000.0	usd
CY2021Q4	ABEO	Fair Value Warrant Liabilities FairValueWarrantLiabilities	9000000.0	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1788000	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1546000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	770000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	179001	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.58
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M29D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	179001	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.58
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M29D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	143907	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	38.58
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y5M1D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6000	usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	35094	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	38.59
CY2024Q1	ABEO	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm1	P7Y2M26D
CY2024Q1	ABEO	Sharebased Compensation Arrangement By Sharebased Payment Award Options Unvested Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedIntrinsicValue1	8000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	7400000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y2M12D
CY2024Q1	ABEO	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue	500000	usd
CY2023Q1	ABEO	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodFairValue	500000	usd

Files In Submission

Name	View Source	Status
0001493152-24-019459-index-headers.html	Edgar Link	pending
0001493152-24-019459-index.html	Edgar Link	pending
0001493152-24-019459.txt	Edgar Link	pending
0001493152-24-019459-xbrl.zip	Edgar Link	pending
abeo-20240331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
abeo-20240331_def.xml	Edgar Link	unprocessable
abeo-20240331_lab.xml	Edgar Link	unprocessable
abeo-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
abeo-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

2024 Q2 Form 10-Q Financial Statement

#000149315224019459 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO ABEONA THERAPEUTICS INC. Stock $abeo

2024 Q2 Form 10-Q Financial Statement

#000149315224019459 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo